The expansion will add 10 KL of SPPS reactor capacity and establish six parallel cGMP manufacturing lines to support peptide development and commercial supply
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.